Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In a recent study, his group and a US team showed the therapy improves cardiac function in a mouse model of the disease.
This post was originally published on this site
